Nymox Pharmaceutical has announced the Immunogenicity results for its drug candidate NX-1207 BPH Program, which has not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug. NX-1207 ...
Tags: Nymox Pharmaceutical, Immunogenicity results, NX-1207 BPH Program
Nymox Pharmaceutical has reported new positive data from Phase 3 study, designed to evaluate the safety and efficacy of the reinjection of NX-1207 for benign prostatic hyperplasia (BPH). The NX02-0020 study participants included 192 ...
Tags: Nymox Pharmaceutical, BPH, Phase 3 study